$MRTX target doubled by Citigroup

Citigroup reiterates buy on Mirati Therapeutics (MRTX) doubling the price target to $16. CIBC and Cann initiate coverage with outperform rating and target of $18. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.